The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
P2X7 in Cancer: From Molecular Mechanisms to Therapeutics
Open accessAbstract
P2X7 is a transmembrane receptor expressed in multiple cell types including neurons, dendritic cells, macrophages, monocytes, B and T cells where it can drive a wide range of physiological responses from pain transduction to immune response. Upon activation by its main ligand, extracellular ATP, P2X7 can form a non-selective channel for cations to enter the cell. Prolonged activation of P2X7, via high levels of extracellular ATP over an extended time period can lead to the formation of a macropore, depolarisation of the plasma membrane and ultimately to cell death. Thus, dependent on its activation state, P2X7 can either drive cell survival and proliferation, or induce cell death. In cancer, P2X7 has recently been shown to have a broad range of functions, including playing key roles in the development and spread of tumour cells. It is therefore unsurprising that P2X7 has been reported to be up-regulated in several malignancies. Critically, ATP is present at high extracellular concentrations in the tumour microenvironment (TME) compared with levels observed in normal tissues. These high levels of ATP should present a survival challenge for cancer cells, potentially leading to constitutive receptor activation, prolonged pore formation and ultimately to cell death. Therefore, to deliver the proven advantages for P2X7 in driving tumour survival and metastatic potential, the P2X7 macropore must be tightly controlled whilst retaining other functions. Studies have shown that commonly expressed P2X7 splice variants, distinct SNPs and post-translational receptor modifications can impair the capacity of P2X7 to open the macropore. These receptor modifications and potentially others may ultimately protect cancer cells from the negative consequences associated with constitutive activation of P2X7. Significantly, the effects of both P2X7 agonists and antagonists in preclinical tumour models of cancer demonstrate the potential for agents modifying P2X7 function, to provide innovative cancer therapies. This review summarises recent advances in understanding of the structure and functions of P2X7 and how these impact P2X7 roles in cancer progression. We also review potential therapeutic approaches directed against the receptor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ROS as signalling molecules: Mechanisms that generate specificity in ROS homeostasis
D'Autréaux, B., & Toledano, M. B. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2256 · Cited by 3,642
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Molecular Physiology of P2X Receptors
North, R. A. (2002) · Physiological Reviews · doi:10.1152/physrev.00015.2002 · Cited by 2,919
GEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
The Cytolytic P 2Z Receptor for Extracellular ATP Identified as a P 2X Receptor (P2X 7 )
Surprenant, A., Rassendren, F., Kawashima, E., North, R. A., & Buell, G. (1996) · Science · doi:10.1126/science.272.5262.735 · Cited by 1,739
Understanding the mechanism of IL-1β secretion
Lopez-Castejon, G., & Brough, D. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.10.001 · Cited by 1,519
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
Gopalakrishnan, V., Helmink, B. A., Spencer, C. N., Reuben, A., & Wargo, J. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.015 · Cited by 1,392 · cited 1×
“This might be significant in view of the known role of microbiota in the pathogenesis of several types of cancer and the influence of microbiota on the response to immune checkpoint inhibitors (Gopalakrishnan et al., 2018; Zitvogel et al., 2018; Vivarelli et al., 2019).”
BackgroundThe P2X7 Receptor in Infection and Inflammation
Di Virgilio, F., Dal Ben, D., Sarti, A. C., Giuliani, A. L., & Falzoni, S. (2017) · Immunity · doi:10.1016/j.immuni.2017.06.020 · Cited by 1,267
ATP drives lamina propria TH17 cell differentiation
Atarashi, K., Nishimura, J., Shima, T., Umesaki, Y., Yamamoto, M., Onoue, M., Yagita, H., Ishii, N., Evans, R., Honda, K., et al. (2008) · Nature · doi:10.1038/nature07240 · Cited by 1,089 · cited 1×
“…of differentiation in type 1 Frontiers in Pharmacology | www.frontiersin.org 9 regulatory cells, promotion of Treg cell death (Aswad et al., 2005; Schenk et al., 2011; Figliuolo et al., 2017) and the differentiation of inflammatory Th17 lymphocytes (Atarashi et al., 2008; Pandolfi et al., 2016).”
BackgroundThe ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
Reinhold, W. C., Sunshine, M., Liu, H., Varma, S., Kohn, K. W., Morris, J., Doroshow, J., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1370 · Cited by 887
The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aar6918 · Cited by 777
Immunity, inflammation and cancer: a leading role for adenosine
Antonioli, L., Blandizzi, C., Pacher, P., & Haskó, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3613 · Cited by 765
Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase
Pellegatti, P., Raffaghello, L., Bianchi, G., Piccardi, F., Pistoia, V., & Di Virgilio, F. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002599 · Cited by 668
Acid sphingomyelinase activity triggers microparticle release from glial cells
Bianco, F., Perrotta, C., Novellino, L., Francolini, M., Riganti, L., Menna, E., Saglietti, L., Schuchman, E. H., Furlan, R., Clementi, E., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.45 · Cited by 615
Gut Microbiota and Cancer: From Pathogenesis to Therapy
Vivarelli, S., Salemi, R., Candido, S., Falzone, L., Santagati, M., Stefani, S., Torino, F., Banna, G. L., Tonini, G., & Libra, M. (2019) · Cancers · doi:10.3390/cancers11010038 · Cited by 586
Qu, Y., Franchi, L., Nunez, G., & Dubyak, G. R. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.3.1913 · Cited by 563
Caloric restriction mimetics enhance anticancer immunosurveillance
Pietrocola, F., Pol, J., Vacchelli, E., Rao, S., Enot, D. P., Baracco, E. E., Levesque, S., Castoldi, F., Jacquelot, N., Yamazaki, T., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.016 · Cited by 542
Parvathenani, L. K., Tertyshnikova, S., Greco, C. R., Roberts, S. B., Robertson, B., & Posmantur, R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209478200 · Cited by 488
ROS production in phagocytes: Why, when, and where?
Dupré-Crochet, S., Erard, M., & Nüβe, O. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1012544 · Cited by 467
The P2X7 receptor: A main player in inflammation
Adinolfi, E., Giuliani, A. L., De Marchi, E., Pegoraro, A., Orioli, E., & Di Virgilio, F. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.12.021 · Cited by 385 · cited 1×
“Role of P2X7 in the Immune Response Analysis of data from P2X7 small molecule inhibitors and genetic knock out of P2RX7 has demonstrated the key role played by P2X7 in inflammation and immunity (Di Virgilio et al., 2017; Adinolfi et al., 2018; Adinolfi et al., 2019) and, as a consequence, in chronic inflammatory disea…”
BackgroundSelf-citationThe P2X 7 Receptor Drives Microglial Activation and Proliferation: A Trophic Role for P2X 7 R Pore
Monif, M., Reid, C. A., Powell, K. L., Smart, M. L., & Williams, D. A. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5512-08.2009 · Cited by 374
Di Virgilio, F., Schmalzing, G., & Markwardt, F. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.01.005 · Cited by 279
Michelsen, K., Yuan, H., & Schwappach, B. (2005) · The EMBO Reports · doi:10.1038/sj.embor.7400480 · Cited by 235
P2X7 Interactions and Signaling – Making Head or Tail of It
Kopp, R., Krautloher, A., Ramírez-Fernández, A., & Nicke, A. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00183 · Cited by 217
Smart, M. L., Gu, B., Panchal, R. G., Wiley, J., Cromer, B., Williams, D. A., & Petrou, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211094200 · Cited by 170
P2X7 receptor activation induces CXCL2 production in microglia through NFAT and PKC/MAPK pathways
Shiratori, M., Tozaki‐Saitoh, H., Yoshitake, M., Tsuda, M., & Inoue, K. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06809.x · Cited by 153 · cited 3×
“P2X7 receptor activation induces CXCL2 production in microglia through NFAT and PKC/MAPK pathways.”
P2X7 receptor‐stimulation causes fever via PGE2 and IL‐1β release
Barberà‐Cremades, M., Baroja‐Mazo, A., Gomez, A. I., Machado, F., Di Virgilio, F., & Pelegrín, P. (2012) · The FASEB Journal · doi:10.1096/fj.12-205765 · Cited by 142
Kataoka, A., Tozaki‐Saitoh, H., Koga, Y., Tsuda, M., & Inoue, K. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05744.x · Cited by 121
Perruzza, L., Gargari, G., Proietti, M., Fosso, B., D’Erchia, A. M., Faliti, C. E., Rezzonico-Jost, T., Scribano, D., Mauri, L., Colombo, D., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.061 · Cited by 114
Graziano, F., Desdouits, M., Garzetti, L., Podini, P., Alfano, M., Rubartelli, A., Furlan, R., Benaroch, P., & Poli, G. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500656112 · Cited by 77
P2X7 Receptor Modulates Inflammatory and Functional Pulmonary Changes Induced by Silica
Monção-Ribeiro, L. C., Faffe, D. S., Santana, P. T., Vieira, F. S., da Graça, C. L. A. L., Marques-da-Silva, C., Machado, M. N., Caruso-Neves, C., Zin, W. A., Borojevic, R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110185 · Cited by 71
Wilkaniec, A., Gąssowska, M., Czapski, G. A., Cieślik, M., Sulkowski, G., & Adamczyk, A. (2017) · Purinergic Signalling · doi:10.1007/s11302-017-9567-2 · Cited by 61
Cited by
Patergnani, S., Danese, A., Bouhamida, E., Aguiari, G., Previati, M., Pinton, P., & Giorgi, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218323 · Cited by 350
Metadata
- Authors
- Lara, R., Adinolfi, E., Harwood, C. A., Philpott, M., Barden, J. A., Di Virgilio, F., & McNulty, S.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2020-06-04
- Volume
- 11
- Pages
- 793-793
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3032938756
- Cited by
- 169
- References
- 35
- FWCI
- 13.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.